Halyard Health, Inc. (HYH) Receives Buy Rating from Stifel Nicolaus

Stifel Nicolaus reaffirmed their buy rating on shares of Halyard Health, Inc. (NYSE:HYH) in a research note released on Friday morning. They currently have a $52.00 price objective on the medical instruments supplier’s stock.

Several other brokerages have also commented on HYH. Zacks Investment Research raised Halyard Health from a sell rating to a hold rating in a research note on Thursday, October 19th. BidaskClub raised Halyard Health from a hold rating to a buy rating in a research note on Saturday, August 19th. Deutsche Bank AG boosted their price target on Halyard Health from $35.00 to $42.00 and gave the stock a buy rating in a research note on Thursday, August 3rd. TheStreet lowered Halyard Health from a b- rating to a c+ rating in a research note on Monday, October 30th. Finally, KeyCorp reissued a hold rating on shares of Halyard Health in a research note on Tuesday, October 17th. Three analysts have rated the stock with a hold rating and five have issued a buy rating to the stock. The stock currently has a consensus rating of Buy and a consensus price target of $44.00.

Shares of Halyard Health (NYSE HYH) traded up $0.33 during trading hours on Friday, hitting $47.33. The stock had a trading volume of 509,701 shares, compared to its average volume of 456,112. The stock has a market cap of $2,216.75, a price-to-earnings ratio of 22.65, a price-to-earnings-growth ratio of 3.16 and a beta of 1.69. The company has a debt-to-equity ratio of 0.49, a current ratio of 2.13 and a quick ratio of 1.11. Halyard Health has a fifty-two week low of $32.60 and a fifty-two week high of $50.99.

Halyard Health (NYSE:HYH) last announced its quarterly earnings results on Wednesday, November 1st. The medical instruments supplier reported $0.60 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.47 by $0.13. The business had revenue of $401.40 million for the quarter, compared to analyst estimates of $394.54 million. Halyard Health had a return on equity of 8.65% and a net margin of 3.52%. The company’s quarterly revenue was up 1.0% on a year-over-year basis. During the same quarter in the previous year, the company earned $0.48 EPS. sell-side analysts expect that Halyard Health will post 2.08 EPS for the current year.

ILLEGAL ACTIVITY WARNING: This piece of content was first published by Community Financial News and is the property of of Community Financial News. If you are viewing this piece of content on another site, it was copied illegally and reposted in violation of US and international copyright laws. The legal version of this piece of content can be read at https://www.com-unik.info/2017/11/05/halyard-health-inc-hyh-receives-buy-rating-from-stifel-nicolaus.html.

Hedge funds have recently bought and sold shares of the stock. Riverhead Capital Management LLC lifted its stake in Halyard Health by 88.1% in the 2nd quarter. Riverhead Capital Management LLC now owns 3,197 shares of the medical instruments supplier’s stock valued at $126,000 after buying an additional 1,497 shares in the last quarter. LS Investment Advisors LLC lifted its stake in Halyard Health by 16.1% in the 2nd quarter. LS Investment Advisors LLC now owns 4,017 shares of the medical instruments supplier’s stock valued at $158,000 after buying an additional 556 shares in the last quarter. Victory Capital Management Inc. lifted its stake in Halyard Health by 17.7% in the 2nd quarter. Victory Capital Management Inc. now owns 4,732 shares of the medical instruments supplier’s stock valued at $186,000 after buying an additional 711 shares in the last quarter. QS Investors LLC lifted its stake in Halyard Health by 305.6% in the 2nd quarter. QS Investors LLC now owns 5,176 shares of the medical instruments supplier’s stock valued at $203,000 after buying an additional 3,900 shares in the last quarter. Finally, Quotient Investors LLC purchased a new stake in Halyard Health in the 3rd quarter valued at approximately $203,000. 91.03% of the stock is currently owned by hedge funds and other institutional investors.

About Halyard Health

Halyard Health, Inc is a medical technology company. The Company operates through two segments: Medical Devices and Surgical and Infection Prevention (S&IP). The Medical Devices segment provides a portfolio of product offerings focused on pain management, respiratory and digestive health. The S&IP segment provides healthcare supplies and solutions that target the prevention of healthcare-associated infections.

Analyst Recommendations for Halyard Health (NYSE:HYH)

What are top analysts saying about Halyard Health Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Halyard Health Inc. and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit